Skip to content

Study · Randomized controlled trial · n = 63 · 2015

10 results

Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.

Ma Z, Chen R, Liu Y, Yu P, Chen L

International journal of clinical pharmacology and therapeutics1 Nov 2015Cited by 12 (Europe PMC)

PMID26365337 (opens in a new tab)DOI10.5414/cp202415 (opens in a new tab)PepBankPUB-26365337
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, FPG decreased after 12 weeks in both the liraglutide and NPH groups.

    In plain wordsIn people with newly diagnosed type 2 diabetes, fasting blood sugar fell with both liraglutide and NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose (FPG) change
    Study

    n = 63

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    FPG, HbAlc, and MBG were decreased in both groups after 12 weeks of treatment.
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, HbA1c decreased after 12 weeks in both the liraglutide and NPH groups.

    In plain wordsIn people with newly diagnosed type 2 diabetes, HbA1c fell with both liraglutide and NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 63

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    FPG, HbAlc, and MBG were decreased in both groups after 12 weeks of treatment.
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, MBG decreased after 12 weeks in both the liraglutide and NPH groups.

    In plain wordsIn people with newly diagnosed type 2 diabetes, average blood sugar fell with both liraglutide and NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean blood glucose (MBG) change
    Study

    n = 63

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    FPG, HbAlc, and MBG were decreased in both groups after 12 weeks of treatment.
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, MAGE was significantly lower with liraglutide than with NPH.

    In plain wordsIn people with newly diagnosed type 2 diabetes, liraglutide gave smaller blood sugar swings than NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseMAGE
    Study

    n = 63

    Comparator
    NPH insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05).
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, SDBG was significantly lower with liraglutide than with NPH.

    In plain wordsIn people with newly diagnosed type 2 diabetes, liraglutide gave smaller blood sugar variation than NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseSDBG
    Study

    n = 63

    Comparator
    NPH insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05).
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, LAGE was significantly lower with liraglutide than with NPH.

    In plain wordsIn people with newly diagnosed type 2 diabetes, the largest blood sugar swings were smaller with liraglutide than with NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseLAGE
    Study

    n = 63

    Comparator
    NPH insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05).
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, BMI was significantly lower with liraglutide than with NPH.

    In plain wordsIn people with newly diagnosed type 2 diabetes, BMI was lower with liraglutide than with NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI
    Study

    n = 63

    Comparator
    NPH insulin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05).
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, waist circumference was significantly lower with liraglutide than with NPH.

    In plain wordsIn people with newly diagnosed type 2 diabetes, waist size was smaller with liraglutide than with NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 63

    Comparator
    NPH insulin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, the MAGE, SDBG, LAGE, BMI, and waist circumference were significantly 1ower than in the NPH group (p<0.05).
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  9. 09HumanRandomized controlled trialSafety outcome

    In newly diagnosed type 2 diabetes, gastrointestinal adverse effects were more frequent with liraglutide than with NPH.

    In plain wordsIn people with newly diagnosed type 2 diabetes, liraglutide caused more stomach and gut side effects than NPH insulin.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal adverse effects
    Study

    n = 63

    Comparator
    NPH insulin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients in the liraglutide group had a greater incidence of gastrointestinal adverse effects than in the NPH group (p<0.05).
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.
  10. 10HumanRandomized controlled trialSafety outcome

    In newly diagnosed type 2 diabetes, hypoglycemia episodes were significantly less frequent with liraglutide than with NPH.

    In plain wordsIn people with newly diagnosed type 2 diabetes, liraglutide caused fewer low blood sugar episodes than NPH insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycemia episodes
    Study

    n = 63

    Comparator
    NPH insulin
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The incidence of hypoglycemia episode in the liraglutide group was significantly lower than in the NPH group (p<0.05).
    2 context sentences
    Summary · context
    A total of 63 newly diagnosed T2DM patients were randomized into a liraglutide group and an NPH group.
    Summary · context
    They were treated for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.